Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays. Its products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also sells its products online. Abcam plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Industry, Sector and Symbol
Industry Industrial inorganic chemicals, not elsewhere classified
Sub-IndustryN/A
SectorMedical
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees1,100
Next Earnings DateN/A
OptionableNot Optionable
ABCAM PLC/ADR (OTCMKTS:ABCZY) Frequently Asked Questions
What is ABCAM PLC/ADR's stock symbol?
ABCAM PLC/ADR trades on the OTCMKTS under the ticker symbol "ABCZY."
How often does ABCAM PLC/ADR pay dividends? What is the dividend yield for ABCAM PLC/ADR?
ABCAM PLC/ADR announced a Semi-Annual dividend on Monday, March 4th. Stockholders of record on Friday, March 15th will be given a dividend of $0.038 per share on Friday, April 26th. The ex-dividend date of this dividend is Thursday, March 14th. View ABCAM PLC/ADR's Dividend History.
Has ABCAM PLC/ADR been receiving favorable news coverage?
Press coverage about ABCZY stock has been trending positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ABCAM PLC/ADR earned a news impact score of 2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
Who are some of ABCAM PLC/ADR's key competitors?
Some companies that are related to ABCAM PLC/ADR include Aurora Cannabis (ACB), WellCare Health Plans (WCG), Quest Diagnostics (DGX), Seattle Genetics (SGEN), Sino Biopharmaceutical (SBMFF), Sonic Healthcare (SHL), Bausch Health Companies (BHC), DexCom (DXCM), IPSEN S A/S (IPSEY), EXACT Sciences (EXAS), DENTSPLY SIRONA (XRAY), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Steris (STE) and Cochlear (COH).
What other stocks do shareholders of ABCAM PLC/ADR own?
Who are ABCAM PLC/ADR's key executives?
ABCAM PLC/ADR's management team includes the folowing people:
- Mr. Alan Thomas Hirzel BS, MS, MBA, CEO & Exec. Director (Age 51)
- Dr. Jonathan Simon Milner, Co-Founder & Non-Exec. Deputy Chairman (Age 54)
- Mr. Gavin Hilary James Wood BA (Hons), ACA, CFO & Exec. Director (Age 49)
- James Staveley, VP of Investor Relations
- Ms. Suzanne E. Smith LLB (Hons), MBA, Chief Legal Officer & Company Sec.
How do I buy shares of ABCAM PLC/ADR?
Shares of ABCZY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ABCAM PLC/ADR's stock price today?
One share of ABCZY stock can currently be purchased for approximately $15.05.
How big of a company is ABCAM PLC/ADR?
ABCAM PLC/ADR has a market capitalization of $3.08 billion. ABCAM PLC/ADR employs 1,100 workers across the globe.
MarketBeat Community Rating for ABCAM PLC/ADR (OTCMKTS ABCZY)
MarketBeat's community ratings are surveys of what our community members think about ABCAM PLC/ADR and other stocks. Vote "Outperform" if you believe ABCZY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABCZY will underperform the S&P 500 over the long term. You may vote once every thirty days.
